Paliperidona Teva (Paliperidone Palmitate)

After intramuscular injection, paliperidone palmitate slowly hydrolyses to paliperidone, which blocks dopamine D2 and serotonin 5‑HT2A receptors in the brain. This antagonism dampens the neurotransmitter activity that underlies hallucinations, delusions, and mood disturbances, thereby stabilising psychotic conditions.

The dosing regimen for Paliperidona Teva is individualized by the prescribing clinician based on the patient’s clinical response, prior oral therapy, and tolerability. The prescriber determines the injection volume, dosing interval (typically monthly or quarterly), and any dose adjustments needed over time.

Data on the use of paliperidone palmitate during pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should be counselled on effective contraception and monitored closely.

To place an order, submit an enquiry on the Paliperidona Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Paliperidona Teva (paliperidone palmitate) offers a once‑monthly or quarterly dosing schedule similar to risperidone long‑acting injection, but it provides a slightly higher receptor affinity for dopamine D2 and a longer half‑life, which can result in more stable plasma concentrations. Choice between products often depends on individual tolerability, metabolic profile, and clinician preference.

The product must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken. Before administration, allow the suspension to reach room temperature as directed in the product label, and inspect for any particulate matter or discoloration.

Paliperidona Teva is given by deep intramuscular injection, usually into the gluteal muscle. The injection is performed by a qualified healthcare professional using aseptic technique. The dosing interval (monthly or quarterly) is selected by the prescriber based on the patient’s treatment plan.

The most serious adverse reactions include neuroleptic malignant syndrome, tardive dyskinesia, severe orthostatic hypotension, and seizures. Patients should be monitored for fever, muscle rigidity, sudden changes in movement, marked blood‑pressure drops, or any seizure activity, and treatment should be discontinued if these events occur.

Paliperidona Teva is contraindicated in patients with known hypersensitivity to paliperidone, paliperidone palmitate, or any excipients in the formulation. It should also be avoided in individuals with a history of neuroleptic malignant syndrome or severe uncontrolled cardiovascular disease. Caution is advised in patients with significant hepatic or renal impairment.